Eligible candidates pursuing hemostasis and/or thrombosis research should apply now for two research-related awards.
Patients with previous hepatitis B infection, cirrhosis or hepatocellular carcinoma need follow-up after treatment with direct-acting antivirals.
Scientists from the Indiana HTC and MicroHealth present the results of a 12-month study on the effect of HTC digital monitoring on annual bleeding rates.
NHF's Medical and Scientific Advisory Council (MASAC) issued the following three new documents, which were adopted by NHF’s Board of Directors on February 28, 2016.
The American Journal of Hematology highlights the careers of female physicians who are movers and shakers in the community.
Despite advancements in therapies, men with severe hemophilia still experience debilitating joint bleeds, lowering their quality of life.
New recombinant factor VIII therapy is expected to reduce the number of weekly prophylactic infusions for those with hemophilia A.
CSL Behring's Idelvion® stays in the bloodstream longer, potentially leading to fewer infusions.
Information in this handy guide is broken down into age groups to help nurses educate and inform the children they treat.
The collaboration will focus on developing adeno-associated viruses (AAVs), delivery vehicles for carrying genetic material, including those for hemophilia.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car